| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 72 | 2023 | 379 | 26.130 |
Why?
|
| Myocardial Infarction | 82 | 2023 | 931 | 15.760 |
Why?
|
| Platelet Aggregation Inhibitors | 66 | 2023 | 399 | 13.290 |
Why?
|
| Rivaroxaban | 21 | 2023 | 211 | 7.190 |
Why?
|
| Stroke | 38 | 2023 | 1016 | 6.700 |
Why?
|
| Acute Coronary Syndrome | 33 | 2024 | 254 | 6.670 |
Why?
|
| Lactones | 24 | 2022 | 56 | 6.600 |
Why?
|
| Pyridines | 27 | 2022 | 425 | 5.970 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 25 | 2023 | 62 | 5.950 |
Why?
|
| Thrombosis | 19 | 2023 | 302 | 5.890 |
Why?
|
| Adenosine | 20 | 2023 | 203 | 5.860 |
Why?
|
| Secondary Prevention | 41 | 2023 | 223 | 5.830 |
Why?
|
| Aspirin | 27 | 2023 | 326 | 5.690 |
Why?
|
| Atherosclerosis | 20 | 2023 | 341 | 5.110 |
Why?
|
| Ischemia | 23 | 2023 | 363 | 4.650 |
Why?
|
| Vascular Surgical Procedures | 11 | 2023 | 262 | 4.300 |
Why?
|
| Endovascular Procedures | 11 | 2023 | 269 | 4.100 |
Why?
|
| Lower Extremity | 19 | 2023 | 337 | 4.040 |
Why?
|
| Hemorrhage | 37 | 2023 | 618 | 3.880 |
Why?
|
| Fibrinolytic Agents | 13 | 2023 | 233 | 3.830 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2024 | 373 | 3.730 |
Why?
|
| Factor Xa Inhibitors | 13 | 2023 | 138 | 3.490 |
Why?
|
| Treatment Outcome | 83 | 2023 | 9159 | 3.330 |
Why?
|
| Cardiovascular Diseases | 26 | 2023 | 1724 | 3.250 |
Why?
|
| Troponin I | 10 | 2022 | 68 | 3.150 |
Why?
|
| Venous Thromboembolism | 11 | 2023 | 234 | 2.900 |
Why?
|
| Anticholesteremic Agents | 7 | 2024 | 129 | 2.900 |
Why?
|
| Aortic Diseases | 5 | 2022 | 95 | 2.770 |
Why?
|
| Diabetes Mellitus, Type 2 | 22 | 2023 | 2098 | 2.750 |
Why?
|
| Brain Ischemia | 8 | 2022 | 298 | 2.700 |
Why?
|
| Humans | 232 | 2024 | 115613 | 2.650 |
Why?
|
| Aged | 111 | 2023 | 19255 | 2.540 |
Why?
|
| Risk Factors | 64 | 2023 | 8699 | 2.510 |
Why?
|
| Thrombolytic Therapy | 8 | 2021 | 118 | 2.480 |
Why?
|
| Drug Therapy, Combination | 23 | 2023 | 962 | 2.220 |
Why?
|
| Drug-Eluting Stents | 4 | 2023 | 62 | 2.200 |
Why?
|
| Diabetes Mellitus | 11 | 2023 | 906 | 2.120 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 488 | 2.110 |
Why?
|
| Middle Aged | 99 | 2023 | 27014 | 2.060 |
Why?
|
| Dyslipidemias | 4 | 2021 | 154 | 2.020 |
Why?
|
| Coronary Artery Disease | 10 | 2021 | 607 | 1.930 |
Why?
|
| Risk Assessment | 28 | 2021 | 2987 | 1.900 |
Why?
|
| Receptor, PAR-1 | 10 | 2019 | 21 | 1.840 |
Why?
|
| Double-Blind Method | 39 | 2021 | 1659 | 1.810 |
Why?
|
| Male | 122 | 2023 | 55968 | 1.800 |
Why?
|
| Female | 120 | 2023 | 59932 | 1.710 |
Why?
|
| Glucosides | 8 | 2020 | 36 | 1.700 |
Why?
|
| Benzhydryl Compounds | 8 | 2020 | 60 | 1.670 |
Why?
|
| Heart Failure | 15 | 2023 | 1964 | 1.660 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2023 | 1218 | 1.640 |
Why?
|
| Anticoagulants | 12 | 2023 | 549 | 1.620 |
Why?
|
| Blood Coagulation Disorders | 2 | 2023 | 196 | 1.400 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2022 | 51 | 1.400 |
Why?
|
| Embolism | 2 | 2022 | 43 | 1.360 |
Why?
|
| Troponin T | 6 | 2022 | 49 | 1.330 |
Why?
|
| Hypolipidemic Agents | 2 | 2021 | 87 | 1.310 |
Why?
|
| Follow-Up Studies | 27 | 2022 | 4440 | 1.270 |
Why?
|
| Extremities | 6 | 2021 | 113 | 1.260 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 25 | 1.250 |
Why?
|
| Cholesterol, LDL | 6 | 2024 | 309 | 1.200 |
Why?
|
| Time Factors | 30 | 2022 | 6165 | 1.140 |
Why?
|
| Piperazines | 8 | 2014 | 314 | 1.130 |
Why?
|
| Receptors, Thrombin | 5 | 2015 | 11 | 1.110 |
Why?
|
| Biomarkers | 28 | 2023 | 3468 | 1.050 |
Why?
|
| Electrocardiography | 8 | 2018 | 560 | 1.050 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 5 | 1.050 |
Why?
|
| Vascular Diseases | 4 | 2023 | 230 | 1.050 |
Why?
|
| Cardiovascular Agents | 4 | 2022 | 125 | 1.040 |
Why?
|
| Sterol O-Acyltransferase | 2 | 2022 | 4 | 1.040 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2021 | 445 | 1.020 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2022 | 815 | 1.000 |
Why?
|
| Hypercholesterolemia | 2 | 2024 | 92 | 1.000 |
Why?
|
| Walking | 5 | 2022 | 425 | 0.990 |
Why?
|
| Myocardial Ischemia | 6 | 2021 | 237 | 0.990 |
Why?
|
| Kidney Diseases | 5 | 2020 | 354 | 0.960 |
Why?
|
| Hospitalization | 9 | 2023 | 1765 | 0.930 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 325 | 0.920 |
Why?
|
| Chest Pain | 4 | 2017 | 82 | 0.910 |
Why?
|
| Cardiology | 3 | 2022 | 260 | 0.890 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2023 | 81 | 0.890 |
Why?
|
| Incidence | 14 | 2023 | 2335 | 0.890 |
Why?
|
| Prasugrel Hydrochloride | 5 | 2020 | 19 | 0.890 |
Why?
|
| Acute Disease | 8 | 2021 | 914 | 0.890 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 467 | 0.880 |
Why?
|
| Acetanilides | 6 | 2014 | 10 | 0.870 |
Why?
|
| Patient Selection | 3 | 2022 | 654 | 0.850 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 2 | 0.840 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 50 | 0.840 |
Why?
|
| Paclitaxel | 2 | 2021 | 192 | 0.770 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2020 | 35 | 0.770 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 82 | 0.750 |
Why?
|
| Proprotein Convertase 9 | 6 | 2021 | 61 | 0.740 |
Why?
|
| Dyspnea | 2 | 2020 | 223 | 0.740 |
Why?
|
| Prospective Studies | 20 | 2022 | 6264 | 0.740 |
Why?
|
| Beneficence | 1 | 2021 | 18 | 0.740 |
Why?
|
| Postoperative Complications | 2 | 2021 | 2161 | 0.740 |
Why?
|
| Platelet Aggregation | 5 | 2023 | 94 | 0.730 |
Why?
|
| Myocarditis | 2 | 2019 | 94 | 0.730 |
Why?
|
| Recurrence | 18 | 2022 | 952 | 0.730 |
Why?
|
| Personal Autonomy | 1 | 2021 | 39 | 0.730 |
Why?
|
| Research Subjects | 1 | 2021 | 41 | 0.730 |
Why?
|
| Sex Characteristics | 2 | 2023 | 641 | 0.720 |
Why?
|
| Renal Insufficiency | 2 | 2021 | 137 | 0.710 |
Why?
|
| Databases, Factual | 3 | 2021 | 1138 | 0.710 |
Why?
|
| Limb Salvage | 5 | 2023 | 52 | 0.710 |
Why?
|
| Diabetes Complications | 2 | 2021 | 212 | 0.710 |
Why?
|
| Cholesterol | 4 | 2022 | 369 | 0.700 |
Why?
|
| Prognosis | 14 | 2023 | 3339 | 0.700 |
Why?
|
| Beverages | 1 | 2020 | 60 | 0.690 |
Why?
|
| Caffeine | 1 | 2020 | 58 | 0.690 |
Why?
|
| Informed Consent | 1 | 2021 | 161 | 0.680 |
Why?
|
| Leg | 1 | 2021 | 227 | 0.670 |
Why?
|
| Consensus | 2 | 2022 | 532 | 0.660 |
Why?
|
| Stents | 4 | 2021 | 475 | 0.650 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2020 | 117 | 0.640 |
Why?
|
| Outpatients | 2 | 2023 | 330 | 0.640 |
Why?
|
| Ezetimibe | 1 | 2018 | 24 | 0.640 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 407 | 0.640 |
Why?
|
| Syndrome | 5 | 2023 | 339 | 0.640 |
Why?
|
| Blood Platelets | 5 | 2023 | 350 | 0.620 |
Why?
|
| Neoplasms | 3 | 2023 | 2118 | 0.620 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2023 | 99 | 0.610 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 296 | 0.600 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2021 | 1870 | 0.600 |
Why?
|
| Proportional Hazards Models | 11 | 2021 | 1087 | 0.580 |
Why?
|
| Survival Rate | 6 | 2021 | 1650 | 0.580 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2023 | 34 | 0.580 |
Why?
|
| Medical Oncology | 1 | 2019 | 230 | 0.580 |
Why?
|
| Disease Management | 1 | 2021 | 563 | 0.580 |
Why?
|
| Heparin | 3 | 2023 | 227 | 0.550 |
Why?
|
| Intermittent Claudication | 4 | 2022 | 108 | 0.550 |
Why?
|
| United States | 18 | 2023 | 12297 | 0.550 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2018 | 160 | 0.530 |
Why?
|
| Enzyme Inhibitors | 5 | 2014 | 757 | 0.530 |
Why?
|
| Patient Readmission | 1 | 2021 | 609 | 0.530 |
Why?
|
| Hypoglycemic Agents | 9 | 2022 | 1008 | 0.520 |
Why?
|
| Cause of Death | 7 | 2021 | 368 | 0.510 |
Why?
|
| Ulcer | 2 | 2021 | 28 | 0.500 |
Why?
|
| Hematoma | 2 | 2021 | 50 | 0.500 |
Why?
|
| Drug Administration Schedule | 8 | 2022 | 724 | 0.500 |
Why?
|
| Hypertension | 2 | 2022 | 1064 | 0.490 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2019 | 16 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1265 | 0.480 |
Why?
|
| Benzazepines | 3 | 2019 | 37 | 0.480 |
Why?
|
| Medicare | 7 | 2023 | 666 | 0.460 |
Why?
|
| Global Health | 4 | 2021 | 290 | 0.460 |
Why?
|
| Thiophenes | 2 | 2011 | 109 | 0.450 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2019 | 35 | 0.450 |
Why?
|
| Quality of Life | 2 | 2022 | 2387 | 0.440 |
Why?
|
| Ranolazine | 7 | 2014 | 22 | 0.430 |
Why?
|
| Life Style | 1 | 2015 | 429 | 0.420 |
Why?
|
| Lecithins | 2 | 2022 | 4 | 0.420 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 14 | 0.420 |
Why?
|
| MicroRNAs | 3 | 2023 | 607 | 0.410 |
Why?
|
| Intracranial Hemorrhages | 5 | 2018 | 76 | 0.410 |
Why?
|
| Cohort Studies | 10 | 2022 | 4945 | 0.410 |
Why?
|
| Stroke Volume | 4 | 2023 | 509 | 0.410 |
Why?
|
| Lipoproteins, HDL | 2 | 2022 | 76 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2392 | 0.400 |
Why?
|
| Multicenter Studies as Topic | 5 | 2021 | 249 | 0.400 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2023 | 161 | 0.400 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 667 | 0.390 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 137 | 0.390 |
Why?
|
| Smoking Cessation | 1 | 2015 | 377 | 0.380 |
Why?
|
| Enoxaparin | 2 | 2021 | 52 | 0.370 |
Why?
|
| Thrombin | 3 | 2021 | 141 | 0.360 |
Why?
|
| Aged, 80 and over | 11 | 2022 | 6419 | 0.360 |
Why?
|
| Angina Pectoris | 2 | 2009 | 62 | 0.360 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2009 | 146 | 0.340 |
Why?
|
| Exercise | 2 | 2021 | 1609 | 0.340 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2021 | 84 | 0.340 |
Why?
|
| Appetite Depressants | 2 | 2019 | 18 | 0.320 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 941 | 0.320 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 196 | 0.320 |
Why?
|
| Hospital Mortality | 3 | 2021 | 779 | 0.310 |
Why?
|
| Troponin | 3 | 2020 | 44 | 0.300 |
Why?
|
| Adult | 19 | 2023 | 30726 | 0.300 |
Why?
|
| Europe | 3 | 2021 | 336 | 0.300 |
Why?
|
| Risk | 5 | 2019 | 819 | 0.300 |
Why?
|
| American Heart Association | 3 | 2022 | 266 | 0.290 |
Why?
|
| Ticlopidine | 5 | 2016 | 55 | 0.290 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2018 | 43 | 0.290 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 324 | 0.290 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 154 | 0.280 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 605 | 0.280 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 1127 | 0.280 |
Why?
|
| Ventricular Function | 1 | 2006 | 57 | 0.270 |
Why?
|
| Internationality | 3 | 2022 | 145 | 0.270 |
Why?
|
| Popliteal Artery | 2 | 2023 | 59 | 0.270 |
Why?
|
| Obesity | 4 | 2019 | 2517 | 0.260 |
Why?
|
| Diabetic Nephropathies | 2 | 2019 | 234 | 0.260 |
Why?
|
| Thromboembolism | 2 | 2021 | 93 | 0.260 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2023 | 29 | 0.250 |
Why?
|
| Angioplasty, Balloon | 3 | 2023 | 90 | 0.250 |
Why?
|
| Peptide Fragments | 2 | 2023 | 675 | 0.250 |
Why?
|
| Immunotherapy | 2 | 2019 | 479 | 0.250 |
Why?
|
| Ankle Brachial Index | 4 | 2022 | 30 | 0.240 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 50 | 0.240 |
Why?
|
| Pravastatin | 2 | 2016 | 28 | 0.240 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2578 | 0.240 |
Why?
|
| Comorbidity | 3 | 2020 | 1473 | 0.240 |
Why?
|
| Cardiovascular System | 2 | 2022 | 124 | 0.230 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2021 | 48 | 0.230 |
Why?
|
| Registries | 5 | 2019 | 1770 | 0.230 |
Why?
|
| Heptanoic Acids | 2 | 2015 | 60 | 0.230 |
Why?
|
| Angioplasty | 1 | 2023 | 40 | 0.220 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2023 | 2 | 0.220 |
Why?
|
| Arteries | 2 | 2022 | 250 | 0.220 |
Why?
|
| Angina, Unstable | 3 | 2013 | 72 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2023 | 12608 | 0.220 |
Why?
|
| Thromboplastin | 1 | 2023 | 71 | 0.220 |
Why?
|
| Pyrroles | 2 | 2015 | 185 | 0.210 |
Why?
|
| Kidney | 2 | 2020 | 1207 | 0.210 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1718 | 0.210 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 1805 | 0.200 |
Why?
|
| Doxorubicin | 1 | 2023 | 290 | 0.200 |
Why?
|
| Liraglutide | 1 | 2022 | 27 | 0.200 |
Why?
|
| Inflammation | 3 | 2023 | 2500 | 0.200 |
Why?
|
| Thiazoles | 1 | 2022 | 110 | 0.200 |
Why?
|
| Glucagon-Like Peptides | 1 | 2022 | 22 | 0.200 |
Why?
|
| Symporters | 1 | 2022 | 52 | 0.200 |
Why?
|
| Numbers Needed To Treat | 1 | 2021 | 8 | 0.200 |
Why?
|
| Mobility Limitation | 1 | 2022 | 60 | 0.200 |
Why?
|
| Warfarin | 1 | 2022 | 136 | 0.200 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2023 | 180 | 0.190 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 14 | 0.190 |
Why?
|
| Myocardial Revascularization | 4 | 2021 | 67 | 0.190 |
Why?
|
| Exercise Therapy | 3 | 2022 | 351 | 0.190 |
Why?
|
| Placebos | 1 | 2021 | 197 | 0.180 |
Why?
|
| Drug Therapy | 1 | 2021 | 78 | 0.180 |
Why?
|
| Heart Diseases | 2 | 2016 | 330 | 0.180 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 228 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 181 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2022 | 140 | 0.180 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 2800 | 0.180 |
Why?
|
| Methylamines | 1 | 2020 | 30 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2021 | 221 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2014 | 1219 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 168 | 0.170 |
Why?
|
| Weight Loss | 3 | 2019 | 633 | 0.170 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 51 | 0.170 |
Why?
|
| Glucagon-Like Peptide Receptors | 1 | 2019 | 1 | 0.170 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 50 | 0.170 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2019 | 36 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 169 | 0.170 |
Why?
|
| Heart | 1 | 2023 | 608 | 0.170 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 74 | 0.170 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 6 | 0.160 |
Why?
|
| Bone Density Conservation Agents | 1 | 2019 | 62 | 0.160 |
Why?
|
| Hemoglobins | 1 | 2021 | 312 | 0.160 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2009 | 20 | 0.160 |
Why?
|
| Pharmacovigilance | 1 | 2018 | 14 | 0.160 |
Why?
|
| Appetite Regulation | 1 | 2019 | 26 | 0.160 |
Why?
|
| Coronary Disease | 2 | 2018 | 348 | 0.160 |
Why?
|
| Microcirculation | 1 | 2019 | 138 | 0.160 |
Why?
|
| Cardiac Rehabilitation | 1 | 2019 | 33 | 0.160 |
Why?
|
| Drug Approval | 2 | 2019 | 78 | 0.160 |
Why?
|
| Platelet Activation | 2 | 2017 | 68 | 0.160 |
Why?
|
| Reoperation | 1 | 2021 | 525 | 0.160 |
Why?
|
| Adamantane | 1 | 2018 | 16 | 0.160 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 576 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1361 | 0.160 |
Why?
|
| Dipeptides | 1 | 2018 | 49 | 0.160 |
Why?
|
| Canagliflozin | 1 | 2018 | 8 | 0.160 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 69 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 145 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 486 | 0.150 |
Why?
|
| Anti-Obesity Agents | 1 | 2018 | 45 | 0.150 |
Why?
|
| Research Personnel | 1 | 2020 | 153 | 0.150 |
Why?
|
| Age Factors | 3 | 2022 | 2907 | 0.150 |
Why?
|
| Inpatients | 1 | 2021 | 380 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 326 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 2 | 2015 | 61 | 0.150 |
Why?
|
| Hyperglycemia | 1 | 2021 | 295 | 0.150 |
Why?
|
| Calibration | 1 | 2018 | 127 | 0.150 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2018 | 98 | 0.150 |
Why?
|
| Overweight | 2 | 2018 | 469 | 0.150 |
Why?
|
| Young Adult | 5 | 2022 | 10487 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2021 | 384 | 0.150 |
Why?
|
| Clinical Chemistry Tests | 2 | 2015 | 9 | 0.140 |
Why?
|
| Pandemics | 2 | 2022 | 1334 | 0.140 |
Why?
|
| Uracil | 1 | 2017 | 31 | 0.140 |
Why?
|
| Morbidity | 1 | 2018 | 278 | 0.140 |
Why?
|
| Intestines | 1 | 2020 | 324 | 0.140 |
Why?
|
| Glycopeptides | 2 | 2014 | 43 | 0.140 |
Why?
|
| Biological Assay | 2 | 2015 | 114 | 0.140 |
Why?
|
| Vascular Patency | 1 | 2016 | 97 | 0.140 |
Why?
|
| Smoking | 2 | 2021 | 1457 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2020 | 497 | 0.140 |
Why?
|
| Pericarditis | 1 | 2016 | 9 | 0.140 |
Why?
|
| Aortitis | 1 | 2016 | 7 | 0.140 |
Why?
|
| Uncertainty | 1 | 2016 | 97 | 0.130 |
Why?
|
| Marketing | 1 | 2016 | 24 | 0.130 |
Why?
|
| Vascular Grafting | 1 | 2016 | 12 | 0.130 |
Why?
|
| Cyclopropanes | 1 | 2016 | 81 | 0.130 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 244 | 0.130 |
Why?
|
| Algorithms | 2 | 2020 | 1491 | 0.130 |
Why?
|
| Piperidines | 1 | 2017 | 163 | 0.130 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 98 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2017 | 223 | 0.130 |
Why?
|
| Adiponectin | 1 | 2017 | 214 | 0.130 |
Why?
|
| ROC Curve | 2 | 2014 | 451 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2017 | 601 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 263 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2023 | 902 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 353 | 0.120 |
Why?
|
| France | 3 | 2019 | 34 | 0.120 |
Why?
|
| Simvastatin | 1 | 2015 | 59 | 0.120 |
Why?
|
| Sleep | 1 | 2020 | 625 | 0.120 |
Why?
|
| Benzaldehydes | 1 | 2014 | 8 | 0.120 |
Why?
|
| Oximes | 1 | 2014 | 19 | 0.120 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 1829 | 0.120 |
Why?
|
| International Cooperation | 2 | 2013 | 174 | 0.120 |
Why?
|
| Veterans | 2 | 2022 | 1234 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1218 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2020 | 588 | 0.110 |
Why?
|
| Bacteria | 1 | 2020 | 729 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2018 | 386 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 503 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 183 | 0.110 |
Why?
|
| Social Media | 1 | 2016 | 135 | 0.110 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 63 | 0.110 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 364 | 0.110 |
Why?
|
| Calgranulin A | 1 | 2012 | 5 | 0.110 |
Why?
|
| Calgranulin B | 1 | 2012 | 7 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2022 | 951 | 0.100 |
Why?
|
| Adolescent | 4 | 2023 | 17903 | 0.100 |
Why?
|
| Prevalence | 4 | 2019 | 2265 | 0.100 |
Why?
|
| Blood Proteins | 1 | 2014 | 238 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 36 | 0.100 |
Why?
|
| Osteoprotegerin | 1 | 2012 | 23 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2022 | 9131 | 0.100 |
Why?
|
| Internet | 1 | 2016 | 602 | 0.100 |
Why?
|
| Models, Biological | 1 | 2018 | 1646 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 2 | 2023 | 174 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 38 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2018 | 805 | 0.100 |
Why?
|
| Protein Precursors | 2 | 2014 | 119 | 0.090 |
Why?
|
| Femoral Artery | 2 | 2022 | 167 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 790 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 356 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 499 | 0.080 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2009 | 2 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2023 | 334 | 0.080 |
Why?
|
| Troponin C | 1 | 2008 | 5 | 0.080 |
Why?
|
| Natriuretic Peptides | 1 | 2008 | 8 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1440 | 0.080 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 24 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2023 | 695 | 0.070 |
Why?
|
| Death | 2 | 2020 | 109 | 0.070 |
Why?
|
| Body Weight | 2 | 2023 | 867 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2023 | 1971 | 0.070 |
Why?
|
| Child | 2 | 2022 | 18487 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2010 | 712 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 590 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 548 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2010 | 770 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2019 | 577 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3023 | 0.060 |
Why?
|
| Factor XI | 1 | 2023 | 6 | 0.060 |
Why?
|
| Absorbable Implants | 1 | 2023 | 34 | 0.060 |
Why?
|
| Everolimus | 1 | 2023 | 63 | 0.060 |
Why?
|
| Inhibins | 1 | 2023 | 45 | 0.050 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2022 | 15 | 0.050 |
Why?
|
| Animals | 5 | 2023 | 32102 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2022 | 30 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 15052 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 210 | 0.050 |
Why?
|
| Sex Factors | 2 | 2021 | 1737 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 61 | 0.050 |
Why?
|
| Therapeutics | 1 | 2022 | 12 | 0.050 |
Why?
|
| Disease Progression | 2 | 2019 | 2418 | 0.050 |
Why?
|
| Tissue Scaffolds | 1 | 2023 | 180 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 684 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 183 | 0.050 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2021 | 57 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 89 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 544 | 0.050 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 70 | 0.050 |
Why?
|
| Pregnancy | 1 | 2012 | 5550 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 446 | 0.050 |
Why?
|
| Drug Labeling | 1 | 2019 | 42 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 666 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 321 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 503 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 353 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2020 | 108 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 58 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2018 | 28 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2019 | 77 | 0.040 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 57 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 639 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2019 | 75 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2018 | 27 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2019 | 79 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 208 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2019 | 78 | 0.040 |
Why?
|
| New Zealand | 1 | 2018 | 48 | 0.040 |
Why?
|
| Sweden | 1 | 2018 | 65 | 0.040 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 44 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 120 | 0.040 |
Why?
|
| Diuresis | 1 | 2018 | 8 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2018 | 77 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 240 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2018 | 39 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 182 | 0.040 |
Why?
|
| Insulin | 2 | 2018 | 2082 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1598 | 0.040 |
Why?
|
| Logistic Models | 1 | 2022 | 1856 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 649 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 180 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 316 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 622 | 0.040 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2017 | 6 | 0.040 |
Why?
|
| England | 1 | 2017 | 63 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 201 | 0.040 |
Why?
|
| Florida | 1 | 2017 | 73 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 820 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2018 | 171 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 904 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 844 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 184 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 293 | 0.030 |
Why?
|
| Marfan Syndrome | 1 | 2016 | 41 | 0.030 |
Why?
|
| Health Promotion | 1 | 2022 | 693 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 126 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 168 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 853 | 0.030 |
Why?
|
| Bone Density | 1 | 2019 | 432 | 0.030 |
Why?
|
| Prediabetic State | 1 | 2018 | 225 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 912 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2015 | 76 | 0.030 |
Why?
|
| Vaccination | 1 | 2023 | 1210 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 290 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 332 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 304 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 795 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 1528 | 0.030 |
Why?
|
| Publishing | 1 | 2016 | 127 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2019 | 372 | 0.030 |
Why?
|
| Metformin | 1 | 2018 | 278 | 0.030 |
Why?
|
| Exercise Test | 1 | 2017 | 539 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 962 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 173 | 0.030 |
Why?
|
| Sodium Channel Blockers | 1 | 2014 | 23 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2014 | 58 | 0.030 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2013 | 55 | 0.030 |
Why?
|
| Massachusetts | 1 | 2014 | 137 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2016 | 342 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2012 | 23 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2019 | 1537 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 430 | 0.030 |
Why?
|
| Norway | 1 | 2012 | 36 | 0.030 |
Why?
|
| Retreatment | 1 | 2012 | 70 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4438 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2011 | 22 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 5060 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2011 | 122 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 181 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 4541 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2009 | 4 | 0.020 |
Why?
|
| Infant | 1 | 2022 | 7976 | 0.020 |
Why?
|
| Angiography | 1 | 2009 | 177 | 0.020 |
Why?
|
| Atherectomy | 1 | 2008 | 33 | 0.020 |
Why?
|
| Echocardiography | 1 | 2010 | 559 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 1749 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2011 | 968 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 318 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 946 | 0.010 |
Why?
|